Cizzle Biotechnology Holdings PLC
CIZ
Company Profile
Business description
Cizzle Biotechnology Holdings PLC is in the early stages of developing a blood test for the early detection of a majority of the different forms of lung cancer. Its proof-of-concept prototype test is based on the ability to detect a stable plasma biomarker, a variant of C1Z1 known as CIZ1B. C1Z1 is a naturally occurring cell nuclear protein involved in DNA replication, and the targeted C1Z1B variant is correlated with early stage lung cancer.
Contact
C/o SGH Secretaries Limited
60 Gracechurch Street
6th Floor
LondonEC3V 0HR
GBRE: cizzle@investor-focus.co.uk
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
2
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 7,530.90 | 316.70 | -4.04% |
| CAC 40 | 7,274.95 | 324.03 | -4.26% |
| DAX 40 | 20,641.72 | 1,075.67 | -4.95% |
| Dow JONES (US) | 38,445.03 | 2,100.90 | -5.18% |
| FTSE 100 | 8,054.98 | 419.76 | -4.95% |
| HKSE | 20,404.62 | 2,445.19 | -10.70% |
| NASDAQ | 15,604.17 | 946.44 | -5.72% |
| Nikkei 225 | 31,744.71 | 2,035.87 | -6.03% |
| NZX 50 Index | 11,833.52 | 391.76 | -3.20% |
| S&P 500 | 5,084.85 | 311.67 | -5.78% |
| S&P/ASX 200 | 7,356.40 | 311.40 | -4.06% |
| SSE Composite Index | 3,130.17 | 211.84 | -6.34% |